Life-threatening adverse drug reactions causing - cardiac failure

Description

Drug-induced cardiac failure arises through direct myocardial toxicity (e.g. anthracycline cardiomyopathy) or through negative inotropic/fluid-retaining effects unmasking or worsening pre-existing cardiac dysfunction - recognising a drug-related cause is essential since discontinuation or dose limitation can prevent progression to irreversible heart failure

A recognised complication of several drug classes, most classically chemotherapy agents (anthracyclines) but also some antiarrhythmics, certain diabetes medications, and NSAIDs (fluid retention worsening pre-existing heart failure)

Anthracycline cardiotoxicity reflects cumulative, dose-dependent direct myocyte damage (oxidative stress-mediated), explaining why lifetime cumulative dose limits are tracked and why baseline/serial cardiac function assessment is required throughout treatment
Negative inotropic drugs (some antiarrhythmics, non-dihydropyridine calcium channel blockers in severe left ventricular dysfunction) can directly worsen contractile function, while fluid-retaining drugs (NSAIDs, some diabetes medications) worsen heart failure through volume/sodium retention rather than direct myocardial toxicity

Baseline cardiac function assessment (echocardiography, sometimes biomarkers) before starting cardiotoxic chemotherapy, with serial monitoring throughout treatment to detect early decline before symptomatic heart failure develops
Cumulative dose tracking for anthracyclines specifically, given the well-established dose-toxicity relationship

Discontinuation or dose reduction of the causative agent where cardiac dysfunction is identified, alongside standard heart failure-directed therapy
Avoiding or using with caution known fluid-retaining/negative inotropic agents in patients with pre-existing significant left ventricular dysfunction

Anthracycline cumulative dose-dependent cardiotoxicity (a key, well-recognised example), NSAID-associated fluid retention worsening heart failure, thiazolidinedione-associated fluid retention and heart failure risk, negative inotropic drug avoidance in severe LV dysfunction

Anthracycline cardiotoxicity is cumulative and dose-dependent, meaning lifetime exposure (not just the current course) must be tracked across a patient's treatment history - this cumulative dose tracking, combined with serial cardiac function monitoring, is what allows early detection and dose limitation before irreversible cardiomyopathy develops

6 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.